Jinzi J. Wu, PhD
Founder, Chairman, Executive Director and Chief Executive Officer
Dr. Jinzi Jason WU (吴劲梓),aged 58, is the Founder of our Group. Dr. Wu was appointed as a Director on February 25, 2014 and was appointed as the chairman of the Board on March 30, 2018. Dr. Wu was redesignated as an executive Director on April 27, 2018. Dr. Wu has served as the chief executive officer of our Group since April 2013. Dr. Wu is primarily responsible for overall management of the business strategy and corporate development of our Group. Dr. Wu is also involved in research and development of all of the candidates in the Group’s pipeline, including but not limited to ASC40, ASC41, ASC42 and ASC22. Dr. Wu also holds the following positions with other members of our Group:
• a director of PowerTree since January 2011;
• a director and chief executive officer of Ascletis BioScience since April 2013;
• a director and chief executive officer of Ascletis Pharmaceuticals since September 2014;
• a director of Ascletis Pharma (China) since March 2018;
• a director and chief executive officer of Ascletis Biopharma since April 2018;
• a director and chief executive officer of Ascletis Xinnuo Medicine since July 2018;
• a director of AP11 Limited since November 2018;
• a director of Sagimet since February 2019;
• a director of SoundRidge Pharmaceuticals (Hong Kong) Co., Limited since April 2019;
• a director and chief executive officer of Gannex Pharma Co., Ltd. Since September 2019; and
• a manager of Gannex, LLC since October 2020.
Dr. Wu has more than 23 years of experience in pharmaceutical research and development. From June 2008 to February 2011, he served as a vice president of HIV Drug Discover Performance Unit at GSK in the U.S., a global pharmaceutical company whose shares are listed on the New York Stock Exchange (ticker symbol: GSK), where he was mainly responsible for discovery and development of multiple preclinical and clinical stage drug candidates. From June 2004 to June 2008, Dr. Wu served as a vice president of Pre-clinical and Basic Research at Ambrilia (formerly known as Procyon), a global biotech company headquartered in Montreal Canada, whose shares were listed on the Canada Stock Exchange (ticker symbol: AMB) and were later delisted on March 4, 2011, where he was mainly responsible for overseeing research and development in areas of anti-viral and anti-cancer drugs. From 2002 to 2004, Dr. Wu also served at PhageTech Inc., an antibiotic discovery company, as a vice president of research and development. Dr. Wu also worked at Immunex Corporation as a group leader of small molecule drug discovery in 2002 prior to joining PhageTech Inc. From 1997 to 2000, Dr. Wu served as a senior scientist at Novartis Pharmaceuticals Corporation, a global pharmaceutical company whose shares are listed on New York Stock Exchange (ticker symbol: NVS), where he was mainly responsible for drug screening.
Dr. Wu received his bachelor’s degree in physiology from Nanjing University (南京大学) in the PRC in July 1985, his master’s degree in physiology from Nanjing University in the PRC in June 1988 and his doctorate degree in cancer biology from University of Arizona in the U.S. in August 1996.
Judy Wu
Executive Director
Mrs. Judy Hejingdao WU (何净岛),aged 47, was appointed as a Director on March 30, 2018 and was re-designated as an executive Director on April 27, 2018. Mrs. Wu also served as a Director of our Company from September 9, 2015 to September 26, 2016. Mrs. Wu is the spouse of Dr. Jinzi Jason WU. Mrs. Wu has served as a vice president of our Group since January 2014. Since joining our Group, Mrs. Wu has actively participated in the daily operations of our Group and she is primarily responsible for overseeing operations of our Group, including management of our human resource and general affairs of our Group, among others. Mrs. Wu also holds the following positions with other members of our Group:
• a director and a vice president of Ascletis BioScience, where she is mainly responsible for operations of the company since January 2014; and
• a vice president of Ascletis Pharmaceuticals where she is mainly responsible for operations of the company since September 2014;
Mrs. Wu received her bachelor’s degree in industrial design from Zhejiang University (浙江大学) in the PRC in July 1996.
Yizhen WEI (魏以桢)
Independent Non-executive Director
Dr. Yizhen WEI (魏以桢),aged 46, was appointed as an independent non-executive Director on April 27, 2018. Dr. Wei is primarily responsible for supervising and providing independent judgement to our Board.
Dr. Wei has over 18 years of experience in clinical medicine industry. Since December 1999, Dr. Wei has served several positions at Fuwai Hospital – China Academy of Medical Science (中国医学科学院阜外医院), including resident physician from December 1999 to September 2003, attending physician from September 2003 to July 2009 and consultant physician then. Dr. Wei was appointed as a medical appraisal expert of Beijing Medical Association (北京市医学会) in December 2013. Dr. Wei has served as a member of the Cardiovascular Committee of the National Cardiovascular Disease Center since August 2016.
Dr. Wei received his bachelor’s degree in clinical medicine in English (英文医学) from China Medical University (中国医科大学) in the PRC in July 1998 and his doctorate degree in Surgery from Chinese Academy of Medical Science & Peking Union Medical College (中国医学科学院北京协和医学院) in the PRC in January 2008.
Jiong GU (顾炯)
Independent Non-executive Director
Mr. Jiong GU (顾炯), aged 48, was appointed as an independent non-executive Director on April 27, 2018. Mr. Gu is primarily responsible for supervising and providing independent judgement to our Board. Mr. Gu is also the chairman of the audit committee of our Board.
Since September 2013 and October 2015, Mr. Gu has served as the chief financial officer of CMC Capital Partners (华人文化产业投资基金), an investment fund specializing in media and entertainment investment in the PRC and globally, and CMC Holdings Limited (华人文化有限责任公司), an investment platform focusing on media and entertainment investments, respectively. From January 2010 to August 2013, Mr. Gu served as the chief financial officer in BesTV New Media Co., Ltd. (百视通新媒体股份有限公司), a PRC company principally engaged in the provision of technical services, content services and marketing services for television terminals, computer terminals and mobile terminals through a media source platforms, whose shares are listed on Shanghai Stock Exchange (stock code: 600637). From April 2004 to December 2009, Mr. Gu successively worked at UTStarcom Telecom Co., Ltd. (UT斯达康通讯有限公司) and its holding company, UTStarcom Inc. a global telecom infrastructure provider specialized in the provision of packet optical transport and broadband access products to network operators, whose shares are listed on Nasdaq (ticker symbol: UTSI), where he was responsible for accounting and financial matters. From July 1995 to April 2004, Mr. Gu had worked for Ernst & Young’s Shanghai office and was the senior manager of the audit department when he left the firm. From June 2015, Mr. GU has been appointed as the independent non-executive director of Xinming China Holdings Limited (新明中国控股有限公司) (HK2699). From June 2015 to November 2020, Mr. Gu was the independent non-executive director of Chen Xing Development Holdings Ltd (辰兴发展控股有限公司) (HK2286). From March 2017, he has been appointed as the independent non-executive director of Amlogic (Shanghai) Co., Ltd (晶晨半导体（上海）股份有限公司) (Stock code: 688099). From September 2018, he has been appointed as the independent non-executive director of Dafa Properties Group Limited (大发地产集团有限公司) (HK6111). From May 2019, Mr. GU has been appointed as the independent non-executive director of Mulsanne Holding Limited (慕尚集团控股有限公司) (HK1817). From June 2019 to November 2020, he was the independent non-executive director of Tu Yi Holding Company Limited (途屹控股有限公司) (HK1701). From December 2020, he has been appointed as the independent non-executive director of Vesync Co., Ltd (HK2148).
Mr. Gu has been a non-practicing member of the Chinese Institute of Certified Public Accountants since April 2004. Mr. Gu received his bachelor’s degree in finance management from Fudan University (复旦大 学) in the PRC in July 1995.
Ms. Lin HUA (华林)
Independent Non-executive Director
Ms. Lin HUA (华林), aged 47, was appointed as an independent non-executive Director on April 27, 2018. Ms. Hua is primarily responsible for supervising and providing independent judgement to our Board.
Since May 2016, Ms. Hua has served as the managing director of Beijing Highgrove Cultural Communication Co., Ltd. (北京海格罗府文化传播有限公司), a company primarily conducted cultural communication activities including organizing exhibitions and introducing and marketing foreign brands into PRC, where she was mainly responsible for overall management of its Greater China operations. From April 2010 to April 2016, Ms. Hua had worked for Yang Guang Xin Ye Real Property Co., Ltd. (阳光新业地产股份有限公司), a real estate development and management company whose shares are listed on the Shenzhen Stock Exchange (stock code: 000608) and served as a vice president of commercial management department when she left. From May 2003 to March 2010, Ms. Hua worked at Verakin Group Company Ltd. (同景集团有限公司), a company primarily conducted real estate development, education, healthcare and tourism and served as board secretary and head of Beijing headquarter when she left. From October 2002 to April 2003, Ms. Hua served as an assistant to producer and program director at China Central Television. From September 1996 to June 2000, Ms. Hua worked at Daiko Pacific International Advertising Inc. (大广太平洋国际广告有限公司), an international advertising company, and she served as a creative director when she left.
Ms. Hua received her bachelor’s degree in industrial design from Zhejiang University in July 1996 and her master degree in distributed computing system from the University of Greenwich in the U.K in June 2002.
